Latest Anti-neutrophil cytoplasmic antibody Stories
In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair.
MOUNTAIN VIEW, Calif., Nov. 10, 2010 /PRNewswire/ -- ChemoCentryx, Inc., today announced favorable Phase I results for CCX168 at the Annual American College of Rheumatology Meeting (ACR).
Investigators have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood vessels.
Researchers have reported that Rituximab, a drug that is FDA approved to treat B cell lymphoma and rheumatoid arthritis, can also treat severe vasculitis as well as the current standard therapy.
Two UNC School of Medicine faculty authored an editorial in the July 15, 2010 New England Journal of Medicine commenting on results from two clinical trials using the drug Rituximab to treat small-vessel vasculitis, a rare autoimmune disease.
SAN DIEGO, Aug. 21 /PRNewswire/ -- Prometheus Laboratories Inc. announced the issuance of U.S. Patent No.
Abstract Wegener's granulomatosis is a multisystemic disease characterized by foci of necrotizing vasculitis and granuloma formation. Subglottic stenosis may occur either as a presenting feature or a late-stage manifestation of the disease, but will occur in approximately 10-20 per cent of cases.
- A trick or prank.